I35.0 D68.01
Conditions
Interventions
Group 1: Patients after surgical aortic valve replacement in the setting of severe aortic stenosis. Measured variabales comprise von Willebrand Factor (western blot), platelet reactivity (Multiplate®
Sponsors
Universitaets-Herzzentrum Freiburg Bad Krozingen Klinik für Kardiologie und Angiologie II
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: Indication for aortic valve replacement (bioprosthetic valve/CoreValve®/Edwards Sapien®), age > 60 years, written informed consent
Exclusion criteria
Exclusion criteria: Prior valvular interventions or cardiac surgery, known severe disorder of the coagulation system, known hematologic disease, severe hepatopathy, hemodialysis, contraindication for treatment with TAVI, peri- or postinterventional transfusions of fresh frozen plasma (FFP), platelets or coagulation factors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fraction of large von Willebrand Factors (vWF) multimeres using western blot at day one and day six after aortic valve replacement | — |
Secondary
| Measure | Time frame |
|---|---|
| Reticulated platelet count (Sysmex XE-2100™), platelet reactivity (Multiplate® Analyzer) and platelet microparticles (Flow cytometry) at day one and day six after aortic valve replacement | — |
Countries
Germany
Contacts
Public ContactThomas Nuehrenberg
Universitaets-Herzzentrum Freiburg - Bad Krozingen Klinik für Kardiologie und Angiologie II Abteilung Klinische Pharmakologie
Outcome results
None listed